Free Trial

LivaNova (LIVN) Competitors

LivaNova logo
$47.17 +0.51 (+1.09%)
Closing price 04:00 PM Eastern
Extended Trading
$47.17 0.00 (-0.01%)
As of 06:04 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

LIVN vs. PEN, STVN, GKOS, BLCO, NARI, IRTC, TMDX, SLNO, INSP, and NVST

Should you be buying LivaNova stock or one of its competitors? The main competitors of LivaNova include Penumbra (PEN), Stevanato Group (STVN), Glaukos (GKOS), Bausch + Lomb (BLCO), Inari Medical (NARI), iRhythm Technologies (IRTC), TransMedics Group (TMDX), Soleno Therapeutics (SLNO), Inspire Medical Systems (INSP), and Envista (NVST). These companies are all part of the "medical equipment" industry.

LivaNova vs. Its Competitors

Penumbra (NYSE:PEN) and LivaNova (NASDAQ:LIVN) are both mid-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their profitability, institutional ownership, analyst recommendations, risk, valuation, earnings, dividends and media sentiment.

Penumbra has a net margin of 3.41% compared to LivaNova's net margin of -17.41%. LivaNova's return on equity of 13.67% beat Penumbra's return on equity.

Company Net Margins Return on Equity Return on Assets
Penumbra3.41% 11.14% 8.40%
LivaNova -17.41%13.67%6.68%

Penumbra has a beta of 0.47, suggesting that its share price is 53% less volatile than the S&P 500. Comparatively, LivaNova has a beta of 0.9, suggesting that its share price is 10% less volatile than the S&P 500.

Penumbra presently has a consensus price target of $305.07, suggesting a potential upside of 25.01%. LivaNova has a consensus price target of $59.29, suggesting a potential upside of 25.69%. Given LivaNova's stronger consensus rating and higher possible upside, analysts plainly believe LivaNova is more favorable than Penumbra.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Penumbra
0 Sell rating(s)
3 Hold rating(s)
13 Buy rating(s)
1 Strong Buy rating(s)
2.88
LivaNova
0 Sell rating(s)
1 Hold rating(s)
6 Buy rating(s)
1 Strong Buy rating(s)
3.00

LivaNova has higher revenue and earnings than Penumbra. LivaNova is trading at a lower price-to-earnings ratio than Penumbra, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Penumbra$1.19B7.91$14.01M$1.06230.23
LivaNova$1.25B2.05$63.23M-$4.09-11.53

88.9% of Penumbra shares are held by institutional investors. Comparatively, 97.6% of LivaNova shares are held by institutional investors. 4.2% of Penumbra shares are held by insiders. Comparatively, 0.3% of LivaNova shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

In the previous week, Penumbra had 6 more articles in the media than LivaNova. MarketBeat recorded 11 mentions for Penumbra and 5 mentions for LivaNova. LivaNova's average media sentiment score of 1.73 beat Penumbra's score of 0.59 indicating that LivaNova is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Penumbra
6 Very Positive mention(s)
1 Positive mention(s)
1 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Positive
LivaNova
3 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Very Positive

Summary

Penumbra and LivaNova tied by winning 8 of the 16 factors compared between the two stocks.

Get LivaNova News Delivered to You Automatically

Sign up to receive the latest news and ratings for LIVN and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding LIVN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

LIVN vs. The Competition

MetricLivaNovaMED INSTRUMENTS IndustryMedical SectorNASDAQ Exchange
Market Cap$2.54B$6.76B$5.50B$8.96B
Dividend YieldN/A1.27%5.25%4.02%
P/E Ratio-11.5317.6019.9019.84
Price / Sales2.0573.22436.90127.27
Price / Cash11.0020.6637.0657.97
Price / Book1.944.748.125.62
Net Income$63.23M$174.76M$3.16B$248.50M
7 Day Performance2.37%1.38%4.40%5.54%
1 Month Performance1.88%0.02%4.09%7.52%
1 Year Performance-6.28%16.46%34.53%22.06%

LivaNova Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
LIVN
LivaNova
3.1989 of 5 stars
$47.17
+1.1%
$59.29
+25.7%
-9.6%$2.54B$1.25B-11.532,900News Coverage
Positive News
PEN
Penumbra
4.831 of 5 stars
$248.05
-1.2%
$302.40
+21.9%
+38.2%$9.72B$1.19B76.314,500Analyst Forecast
STVN
Stevanato Group
1.1556 of 5 stars
€24.23
-1.5%
N/A+35.0%€7.34B€1.19B47.515,521Positive News
GKOS
Glaukos
4.377 of 5 stars
$101.69
-1.7%
$134.67
+32.4%
-16.3%$5.91B$383.48M0.00780
BLCO
Bausch + Lomb
2.9341 of 5 stars
$13.83
-0.4%
$15.54
+12.4%
-8.2%$4.91B$4.79B28.9213,500Analyst Forecast
NARI
Inari Medical
N/A$79.97
flat
$69.22
-13.4%
N/A$4.68B$493.63M-59.24800
IRTC
iRhythm Technologies
1.0339 of 5 stars
$139.22
-2.3%
$138.60
-0.4%
+40.4%$4.55B$591.84M0.002,000
TMDX
TransMedics Group
1.7035 of 5 stars
$125.17
-3.1%
$127.33
+1.7%
-16.4%$4.37B$441.54M94.99210
SLNO
Soleno Therapeutics
4.4395 of 5 stars
$85.27
-1.6%
$107.10
+25.6%
+101.0%$4.37BN/A0.0030
INSP
Inspire Medical Systems
4.811 of 5 stars
$127.11
-1.1%
$211.91
+66.7%
-1.7%$3.79B$802.80M59.211,246News Coverage
Positive News
NVST
Envista
3.9247 of 5 stars
$19.66
-3.6%
$20.23
+2.9%
+22.8%$3.46B$2.51B28.7212,300Positive News
Analyst Forecast

Related Companies and Tools


This page (NASDAQ:LIVN) was last updated on 7/9/2025 by MarketBeat.com Staff
From Our Partners